Cajanin 

Cajanin is a potent and orally active anti-melanogenic agent. Cajanin shows antiproliferative activity in MNT1 Cells. Cajanin efficiently decreases the melanin content. Cajanin down-regulates the mRNA and protein expression levels of MITF, tyrosinase, TRP-1 and Dct (TRP-2). Cajanin induces cell cycle arrest at G2/M and S phase. Cajanin stimulates osteoblast proliferation. Cajanin has the potential for the research of human hyperpigmented disorders and menopausal osteoporosis^[1][2].

Cajanin shows strong mitogenic as well as differentiation-promoting effects on osteoblasts^[2].
Cajanin induces the phosphorylation of both Erk1/2 and Akt^[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cajanin (10 mg/kg, p.o.; daily for 30 consecutive days) increases the BMD levels in all anatomical regions of the skeleton studied in Sprague Dawley rats^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

300.26

C₁₆H₁₂O₆

32884-36-9

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Netcharoensirisuk P, et al. Cajanin Suppresses Melanin Synthesis through Modulating MITF in Human Melanin-Producing Cells. Molecules. 2021 Oct 5;26(19):6040.  [Content Brief]

  [2]. Bhargavan B, et al. Methoxylated isoflavones, cajanin and isoformononetin, have non-estrogenic bone forming effect via differential mitogen activated protein kinase (MAPK) signaling. J Cell Biochem. 2009 Oct 1;108(2):388-99.  [Content Brief]

  [3]. Wensaas AJ, et al. Fatty acid incubation of myotubes from humans with type 2 diabetes leads to enhanced release of beta-oxidation products because of impaired fatty acid oxidation: effects of tetradecylthioacetic acid and eicosapentaenoic acid. Diabetes. 2009 Mar;58(3):527-35.  [Content Brief]